Further progress on the stake sale; Valuation wise does not appear to be very attractive for retail investor given the price paid by Advent is close to current valuation. Am I missing something.
| Subscribe To Our Free Newsletter |
Suven Pharma ~ Demerged CRAMS Arm of Suven Life Sciences
